Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

BACKGROUND: Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in the Comprehensive Cancer Center Ostbayern (CCCO) from 2019 to 2021. METHODS AND RESULTS: In total, 251 patients were included. Targete...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheiter, Alexander, Hierl, Frederik, Lüke, Florian, Keil, Felix, Heudobler, Daniel, Einhell, Sabine, Klier-Richter, Margit, Konstandin, Nikola P., Weber, Florian, Scheiter, Andrea, Kandulski, Arne, Schlosser, Sophie, Cosma, Lidia-Sabina, Tews, Hauke, Weiss, Andreas R. R., Grube, Matthias, Bumes, Elisabeth, Hau, Peter, Proescholdt, Martin, Steger, Felix, Troeger, Anja, Haferkamp, Sebastian, Reibenspies, Lucas E., Schnabel, Marco J., Schulz, Christian, Drexler, Konstantin, Hatzipanagiotou, Maria E., Seitz, Stephan, Klinkhammer-Schalke, Monika, Unberath, Philipp, Calvisi, Diego F., Pukrop, Tobias, Dietmaier, Wolfgang, Evert, Matthias, Utpatel, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006213/
https://www.ncbi.nlm.nih.gov/pubmed/36572733
http://dx.doi.org/10.1038/s41416-022-02120-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006213/
https://www.ncbi.nlm.nih.gov/pubmed/36572733
http://dx.doi.org/10.1038/s41416-022-02120-x

Ejemplares similares